Thermo Fisher Scientific Inc logo

Thermo Fisher Scientific Inc

TMO
Last price US$570.00
Market cap US$196.1b
12M price change 19.71%
Loading the 12-month Mave Thesis and 1-month news signal

Dashboard Funda..tals Prediction Screener Map

Thermo Fisher Scientific Inc Overview

Industry: Diagnostics & Research

Sector: Healthcare

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the United States and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, clinical next-generation sequencing, bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, laboratory chemicals, research and safety market channel, and pharma services and clinical research. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts. Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the United States and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biol Read More

Mavefund brings filings, fundamentals, valuation, price history and news for Thermo Fisher Scientific Inc into one research view. The sections below show what strengthens or weakens the research case.

Score

Reported Results

What the company reported, with filing details kept small.

Filed Jul 23, 2026

Quarterly result summary

Revenue was $12B (+10% YoY); EPS was $6.03 (reported).

Revenue $12B +10% YoY
EPS $6.03 reported
Operating income $2.1B +11894% YoY
Net income $1.7B +8% YoY

What changed

  • Revenue +10% YoY to $12B; EPS reported to $6.03.
  • Operating income +11894% YoY to $2.1B.
  • Net income +8% YoY to $1.7B.

Guidance / outlook

No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.

Earnings release Open filing

Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

Other recent earnings materials

Prediction-grade evidence

Recent News

Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

Earnings Per Share

Score 3.00/5
Thermo Fisher Scientific Inc boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
In Diagnostics & Research industry , IQVIA Holdings Inc , Agilent Technologies Inc , Medpace Holdings Inc are companies with high ratings.

Return on Equity

Score 4.44/5
Thermo Fisher Scientific Inc stands out with a superior score in the Return on Equity (ROE) section, surpassing the sector median value and showcasing its strong performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
Thermo Fishe... TMO US$196.1b
Zoetis Inc ZTS US$31.9b
IQVIA Holdin... IQV US$34.8b
Agilent Tech... A US$37.9b

Net Margin

Score 4.79/5
Thermo Fisher Scientific Inc commands a high score, propelled by its net margin consistently outpacing the sector median value and exhibiting continuous growth in recent six years; noteworthy counterparts in the sector, boasting similarly high scores, include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
Thermo Fishe... TMO US$196.1b
Zoetis Inc ZTS US$31.9b
IQVIA Holdin... IQV US$34.8b
Agilent Tech... A US$37.9b

Share Buyback

In Diagnostics & Research industry , IQVIA Holdings Inc , Agilent Technologies Inc , Medpace Holdings Inc are companies with high ratings.

Leverage

Score 3.25/5
Thermo Fisher Scientific Inc attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc , also exhibit high scores.
Thermo Fishe... TMO US$196.1b
Zoetis Inc ZTS US$31.9b
IQVIA Holdin... IQV US$34.8b
Agilent Tech... A US$37.9b

Financial Statements

Company-reported SEC EDGAR facts organized into the three core statements.

Verified SEC statements load when this section enters view.

Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

Financial Ratio

Yearly Quarterly

Financial
Profitability
Growth
Cash Flow
Financial Health
Efficiency Ratios

Thermo Fisher Scientific Inc logo

Thermo Fisher Scientific Inc

US$570.00

US$182.75

-67.9% vs price

US$196.1b

6.46%

19.71%